The Validation of GARDskin

Johansson A, Agemark M, Gradin R, Larne O, Appelgren H, Forreryd A, Jerre A, Edwards A, Hoepflinger V, Burleson F, Gehrke H, Roggen E, Johansson H
SenzaGen, Lund, Sweden, Burleson Research Technologies, Morrisville, US, Eurofins, Munich, Germany

The prevalence of allergic contact dermatitis (ACD) is estimated to >20% in the western world. Not only the individual is affected, but downstream socioeconomic effects are high. To minimize exposure, chemicals must be safety tested. Traditional testing strategies like the murine local lymph node assay (LLNA) comprise animals, but the regulatory authorities, public opinion and economic interests require animal-free models. The Genomic Allergen Rapid Detection skin (GARDskin) is an in vitro assay addressing this need. Here, we present the results of the GARDskin ring trial (OECD TGP 4.106) for validity of the assay.

Transfer study
Transferability: 100%

Validation study
WLR: 82 – 89%BLR: 92% (92 – 100%)

Test performance
Accuracy: 94%Sensitivity: 93%Specificity: 96%

A blinded ring trial was performed to assess the functionality of the GARDskin assay. The data demonstrates that GARDskin is a powerful tool for assessment of chemical skin sensitizers, with a predictive accuracy of 94% and excellent reproducibility between laboratories.


Performance of the GARD assay in a blind Cosmetics Europe study

Johansson H, Gradin R, Forreryd A, Agemark M, Zeller K, Malmborg-Hager A1, Johansson A, Larne O, Van Vliet E3, Borrebaeck C, Lindstedt M,
SenzaGen AB, Lund, Sweden, Department of Immunotechnology, Lund University, Lund, Sweden, Cosmetics Europe –The Personal Care Association, Brussels, Belgium


Chemical hypersensitivity is an immunological response to foreign substances. Primarily, these give rise to the clinical symptoms known as allergic contact dermatitis. To mitigate risks associated with consumer products, chemicals are screened for sensitizing effects. Historically, such predictive screenings have been performed using animal models, but industrial and regulatory authorities now demand animal-free methods for the assessment of sensitization. This is a global development spreading across industries and markets. To meet this demand, the Genomic Allergen Rapid Detection (GARD) assay has been developed. Here, we present novel data reconfirming the performance and accuracy of GARD.


The performance of GARD is highly accurate
83% (72 chemicals)
86% (127 chemicals)
83% (72 chemicals)
Correlated GARD predictions and potency classifications